Literature DB >> 2377209

The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.

D R Karp1, C L Teletski, P Scholl, R Geha, E O Long.   

Abstract

Several exoproteins from the bacterium Staphylococcus aureus are highly potent polyclonal activators of T cells in the presence of cells bearing class II antigens of the major histocompatibility complex (MHC). These toxins, including the toxic shock syndrome toxin (TSST-1), act at nanomolar concentrations, bind directly to class II molecules, and do not require the processing typical of nominal antigen. Each toxin is capable of stimulating a subpopulation of peripheral T lymphocytes bearing particular V beta sequences as part of their alpha beta T-cell receptors. It is not known how these so-called 'superantigens' bind to class II and how this binding stimulates T cells. In this study, the different affinities of TSST-1 for human class II molecules DR and DP were exploited to define the region of a class II molecule necessary for high-affinity binding. Using chimaeric alpha- and beta-chains of DR and DP expressed at the surface of transfected murine fibroblasts and a binding assay with TSST-1, it was shown that the alpha 1 domain of DR is essential for high-affinity binding, and further that TSST-1 binding did not prevent subsequent binding of a DR-restricted antigenic peptide. This is compatible with a model of superantigen making external contacts with both class II and T cell receptor, and suggests that the V beta portion of the T-cell receptor interacts with the nonpolymorphic alpha-chain of DR.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2377209     DOI: 10.1038/346474a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  25 in total

1.  Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.

Authors:  D R Karp; R N Jenkins; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

2.  Dual antigenic recognition by cloned human gamma delta T cells.

Authors:  J Holoshitz; L M Vila; B J Keroack; D R McKinley; N K Bayne
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

3.  Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B.

Authors:  K Imanishi; H Igarashi; T Uchiyama
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

4.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

5.  Both alpha-helices along the major histocompatibility complex binding cleft are required for staphylococcal enterotoxin A function.

Authors:  J K Russell; C H Pontzer; H M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

Review 6.  Evidence for a superantigen in the pathogenesis of tuberculosis.

Authors:  J D Ohmen; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1996

Review 7.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

8.  Major histocompatibility complex class II binding site for streptococcal pyrogenic (erythrogenic) toxin A.

Authors:  U F Hartwig; D Gerlach; B Fleischer
Journal:  Med Microbiol Immunol       Date:  1994-11       Impact factor: 3.402

9.  Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.

Authors:  M Dohlsten; G Hedlund; E Akerblom; P A Lando; T Kalland
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

10.  Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.

Authors:  B G Stiles; T Krakauer; P F Bonventre
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.